BIIB - Cognition Therapeutics stock rises after CT1812 shows promise in Alzheimer's study

2023-05-18 11:30:11 ET

Cognition Therapeutics ( NASDAQ: CGTX ) stock rose ~9% on Thursday after the company said data for CT1812 was published in the journal Translational Neurodegeneration .

The manuscript is titled, 'A Phase 1b Randomized Clinical Trial of CT1812 to Measure A? Oligomer Displacement in Alzheimer’s Disease Using an Indwelling CSF Catheter.'

"Data from the Phase 1b SNAP study (COG0104, NCT03522129) mirror findings from our preclinical studies showing A? oligomer displacement from neurons in culture and into the CSF in transgenic mice," said Mary Hamby, VP of Research.

The study, dubbed SNAP, enrolled three adults with mild-to-moderate Alzheimer’s disease who received either CT1812 or placebo.

Data showed that a single oral dose of CT1812 rapidly displaces A? oligomers from synapses. This was shown by a temporal increase in CSF A? oligomer levels after a single dose. In contrast, no change was sen in A? oligomers levels after giving placebo, according to the company.

Cognition Therapeutics noted that CT1812 was well-tolerated and no serious adverse events were due to the study drug but were due to the lumbar puncture procedure for the indwelling catheter used for cerebrospinal fluid (CSF) sampling.

Eli Lilly's Donanemab: The Anti-Amyloid Saga Continues

Eli Lilly's Alzheimer's Breakthrough: A Game Changer For Investors And Patients

For further details see: